Nigeria starts clinical trials for own Covid-19 vaccines

Move seen as a major boost to the morale and image of Nigeria’s medical research industry.

It has been confirmed that clinical trials for two vaccines developed by Nigerian scientists have gotten underway. This was confirmed by Boss Mustapha, who is chairman of the Presidential Task Force on COVID-19 and government secretary. "The vaccines will be used after completing clinical trials and obtaining certification," said Mustapha. "This is a welcome development that will open a new vista in scientific breakthrough and will boost the morale and image of the medical industry in the country." Mustapha urged the relevant agencies to provide the necessary support and enabling environment to smoothen the certification process so other researchers can also be motivated to follow suit.

Having taken delivery of four million doses of the Oxford-Astrazeneca’s Covishield vaccines from the Covax initiative to date, Africa’s most populous country received an additional 100,000 doses of the vaccine manufactured by the Serum Institute of India on Tuesday. Overall, the country expects 16 million doses of Oxford-Astrazeneca’s vaccine as part of its plan to vaccinate 70 percent of its population between 2021 and 2022. By Monday, Nigeria had vaccinated 963,802 of its citizens with the first dose of the Covid-19 vaccine. According to data from the Nigeria Center for Disease Control, the country has recorded more than 160,000 confirmed Covid-19 cases with just over 2,000 deaths to date.